来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置首页>技术资料首页>行业动态>公司动态>Decision Diagnostics对强生子公司提起反诉

Decision Diagnostics对强生子公司提起反诉

Decision Diagnostics2013年8月2日 8:59 点击:2202

Decision Diagnostics

 2013年8月1日 Decision Diagnostics Corp宣布,旗下子公司Pharma Tech Solutions针对JNJ两家子公司Lifescan与Lifescan Scotland提起反诉,控告JNJ子公司广告不实与误导。
 

August 01, 2013 09:15 ET

Decision Diagnostics Subsidiary Makes Move and Sues Two Johnson and Johnson Divisions for False Advertising in Ongoing Battle

 

 

LOS ANGELES, CA--(Marketwired - Aug 1, 2013) - Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip™, the Green Glucose Test Strip, specifically designed to work with Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, announced today the filing of counterclaims by its subsidiary Pharma Tech Solutions, Inc. for false and misleading advertising against two of Johnson & Johnson, Inc. ("J&J") wholly owned subsidiaries, Lifescan, Inc., and Lifescan Scotland, LTD (collectively "Lifescan"). The company and its Pharma Tech Solutions, Inc. ("Pharma Tech") subsidiary have been in patent litigation with the Lifescan subsidiaries since September 2011.

J&J's wholly owned subsidiary Lifescan manufactures and sells blood glucose monitoring systems, which include meters and test strips, under the OneTouch® Ultra® brand name. Lifescan is the market share leader in the at-home glucose testing market. The company's Pharma Tech subsidiary competes directly with J&J Lifescan in the market for at-home glucose test strips by offering the Shasta GenStrip, a unique diagnostic testing strip, that has received FDA clearance for at-home use with certain OneTouch® Ultra® meters. The GenStrip is a lower-cost alternative to the OneTouch® Ultra® test strip that works with specific OneTouch® Ultra® meters and costs significantly less than the J&J Lifescan product.

In 2012, immediately following FDA clearance of the GenStrip, Lifescan moved the Federal District Court to enjoin sales and distribution of the competitive GenStrip. While a Federal District Court for the Northern District of California granted Lifescan a preliminary injunction, the Federal Circuit Court quickly stayed the injunction and the matter currently awaits a near term ruling.

Today, Pharma Tech seeks leave from the District Court, in the court room of a judge new to the aforementioned September 2011 case, to amend its counterclaim against J&J Lifescan, based on anti-competitive actions by Lifescan, so that a claim for false advertising can be added.

J&J Lifescan promotes its OneTouch® Ultra® system as having "Double Sure technology," which supposedly "automatically checks... each blood a sample twice to assure that [the user is] receiving the most accurate results." By this representation, J&J Lifescan falsely conveys to consumers that its OneTouch® Ultra® system provides more accurate results than the competition, including the GenStrip. By virtue of proposed amendment to its counterclaim, Pharma Tech intends to prove that this representation is misleading and untrue and that OneTouch® Ultra® system actually likely provides less accurate results than much of its competition.

DECN's Pharma Tech subsidiary is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies. The FDA cleared Shasta GenStrip™ product was first introduced to the market in late 2012 as a lower cost (50%) alternative for user/owners of the J&J LifeScan OneTouch® Ultra®, Ultra2® and Ultra Mini® glucose meters.

Forward-Looking Statements: 
This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates," "will" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.

For further information about Shasta Genstrip, please visit the company's Web Sites: http://www.decisiondiagnostics.com orhttp://www.shastagenstrip.com. The company's Genstrip videos can be viewed at http://www.pharmatechdirect.com. A new video is currently in production.

GenStrip test strips are a product of Shasta Technologies, LLC and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan®, Inc. a Johnson & Johnson® Company, manufacturers and distributors of the OneTouch® Ultra® Family of Meters and OneTouch® Ultra® test strips.


 

(来源: Decision Diagnostics )


全年征稿 / 资讯合作

联系邮箱:kefu@labbase.net

版权与免责声明

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, //www.next-search.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。